Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics (OTCQB: SEOVF) generates frequent news as a clinical-stage regenerative medicine company advancing its Cell Pouch Bio-hybrid Organ platform for type 1 diabetes (T1D) and other chronic diseases. Its announcements focus on clinical progress, scientific collaborations, financing activities, and corporate developments that shape the trajectory of its T1D and thyroid disorder programs.
News releases from Sernova highlight interim data from its ongoing Phase 1/2 clinical trial in T1D, including reports of islet engraftment in the Cell Pouch, insulin production indicated by C-peptide, achievement of insulin independence in some patients, and improvements in HbA1c and patient-reported quality-of-life measures. These updates are central for readers tracking how the Cell Pouch Bio-hybrid Organ performs in people living with T1D, particularly those with hypoglycemia unawareness and severe hypoglycemic episodes.
Investors and observers can also follow collaborations and partnerships, such as Sernova’s agreements with Evotec for stem cell-derived islet-like clusters and with Eledon Pharmaceuticals to evaluate the immunosuppressive agent tegoprubart in a future cohort of its T1D trial. In addition, Sernova regularly reports on financing transactions, including loans, convertible debentures, and debt-to-equity conversions, which the company states are used to support working capital and clinical development plans.
Corporate governance and leadership changes, conference presentations, and updates from the company’s Data and Safety Management Board (DSMB) also appear in Sernova’s news flow. This page aggregates these items so readers can review clinical milestones, partnership developments, and capital structure updates related to Sernova Biotherapeutics and its SEOVF listing in one place.
Sernova Corp. (OTCQB: SEOVF) will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022, and the LifeSci Partners HealthTech Symposium on September 20-21, 2022. CEO Dr. Philip Toleikis will present at both events, with the Wainwright presentation scheduled for September 13 at 9:00 AM ET. The company aims to highlight its regenerative medicine technologies, including the Cell Pouch System for chronic diseases like diabetes. For more details, visit Sernova's investor events page.
Sernova Corp. (OTCQB:SEOVF) announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30, 2022. Dr. Mahony, an experienced biopharma entrepreneur, has over 25 years in healthcare investment and management. He previously co-headed Healthcare at Polar Capital, managing over $4 billion in assets. His expertise spans biotechnology and healthcare services, which will be vital for Sernova's focus on regenerative medicine. Dr. Mahony replaces Dr. Dohrmann as Evotec’s representative and aims to advance Sernova’s Cell Pouch System for chronic diseases.
Sernova Corp. has completed the second tranche of a private placement with Evotec SE, issuing 2,709,800 common shares at $2.50 per share, raising a total of $6,774,500. This brings Evotec's total investment in Sernova to $27,098,000. Sernova aims to utilize these funds for general working capital while advancing its diabetes stem cell initiative and other regenerative therapies. The company currently holds $50 million in cash, bolstered by recent warrant exercises totaling $4,493,587. The firm’s Cell Pouch System is in Phase 1/2 trials for type 1 diabetes.
Sernova Corp. (OTCQB: SEOVF) will host a virtual webcast on September 08, 2022, at 1:00 PM ET. Dr. Philip Toleikis, President & CEO, will participate in a fireside chat moderated by Dr. Douglas Loe, a healthcare analyst. Investors can register and submit questions during the event. The company focuses on regenerative medicine, specifically developing the Cell-Pouch System for chronic diseases such as insulin-dependent diabetes and hemophilia A. Sernova collaborates with the University of Miami and Evotec to advance its therapeutic technologies.
Sernova Corp. (OTCQB: SEOVF), a clinical-stage regenerative medicine company, announced participation in the Truist Securities Cell Therapy Symposium on June 28, 2022. CEO Dr. Philip Toleikis will present on 'Cell Therapy for Non-Oncology Indications' from 2:00-3:00 PM ET at the Lotte New York Palace. Sernova focuses on developing its innovative Cell-Pouch System for chronic diseases like insulin-dependent diabetes, showcasing its potential for a 'functional cure' in ongoing studies. The company also partners with Evotec for iPSC-based therapies, targeting millions with diabetes.
Sernova Corp. (OTCQB:SEOVF) presented promising clinical data on its Cell Pouch System for treating type 1 diabetes at the ADA 82nd Scientific Sessions. The Phase 1/2 trial revealed that three of six patients achieved insulin independence for over 2 years, with positive serum C-peptide values indicating active insulin production. The Cell Pouch has been well tolerated, with implantation durations exceeding 35 months. Future trials will focus on optimizing patient outcomes and utilizing a higher-capacity Cell Pouch. The company aims to provide a functional cure for insulin-dependent diabetes.
Sernova Corp. (OTCQB: SEOVF) and Evotec SE have announced a strategic partnership to develop an off-the-shelf cell replacement therapy for insulin-dependent diabetes. The collaboration leverages Sernova's Cell Pouch System with Evotec's iPSC-based insulin-producing beta cells. Evotec will invest CAD $27 million in Sernova, enhancing the partnership aimed at providing a scalable solution for diabetes treatment. Both companies will fund preclinical development together, with Sernova acquiring options for exclusive licensing of Evotec's beta cells.